APR Nov/Dec 2022 - 26

Tableting
with
Coprocessed
Excipients
BENEFITS OF COPROCESSED
EXCIPIENTS FOR YOUR
TABLETING PROCESS
Coprocessed excipients, defined as " the
combination of two or more excipients
designed to physically modify their
properties without any chemical change "
(IPEC), are increasingly being used as a smart
and effective solution to overcome API challenges to reduce
formulation complexity in direct compression applications.
The main objective when developing a
coprocessed excipient is to enhance its
material properties, combining the
most relevant functionalities, as filler,
binder, disintegrant, and lubricant, in
a single material to improve drug
processability while ensuring excellent product
performance. These enhanced excipient assets
result in cost savings, faster drug development,
and reduced time-to-market.
API and coprocessed excipients normally fulfill the minimum functional requirements for
tableting, simplifying formulation development, and consolidating Quality by Design
efforts. It also minimizes testing expenses by reducing Quality Control analysis,
as well as material handling, and documentation.
By eliminating the need to separately source, test, and blend multiple excipients
with the functionality required; coprocessed excipients reduce weighing and
dispensing steps, enabling a quicker process with fewer associated costs.
Development is accelerated, the formulation is simplified, and manufacturing
complexity is reduced, without compromising technical performance or product quality.
BENEFITS
Cost Savings
Faster Drug Development
Reduced Time-to-Market
FEATURES
Enhanced Functional
Material Properties
Optimized
Performance
Solve API's
Blending and
Processing
Challenges
Coprocessed
excipients offer
enhanced flowability,
compressibility, and
disintegration
APR Nov/Dec 2022

Table of Contents for the Digital Edition of APR Nov/Dec 2022
